AI is reshaping drug discovery economics by improving success rates and reducing development time and cost, potentially enabling pharma companies to earn "valuation credit" like software businesses and spawning a wave of AI-native biotech startups building discovery platforms or their own therapeutics.
Topics: Biotech & Life Sciences · AI Infrastructure · Healthcare
Published by A16Z · their site ↗
SandHill indexes 800+ venture capital blogs and newsletters and sends the best of them every Sunday. Browse the sources · browse by topic · read the blog.
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.